Orchid Chemicals and Pharmaceutical received approval from the USFDA for its abbreviated new drug application (ANDA) of Cephalexin oral suspension. This is an off-patent molecule that forms part of Orchid's distribution alliance with US generic pharma major, Par Pharmaceuticals, Inc.
The company believes that given the complexity of the formulation, it would have a good positioning in the generics market. Its Cephalexin capsules are already marketed in the US in distribution partnership with Par. With the latest ANDA approval, the number of dosage forms, oral solids and injections, distributed by Orchid in the US stands at 12.